# US 8,540,998 B2 · Methods for treating cancer using ephrin type-A receptor 10 antibodies conjugated to cytotoxic agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,540,998 B2
- Document ID: US8540998B2
- Status: Granted
- Kind: B2
- Application number: 12/810,095
- Filed: 2008-12-24
- Published: 2011-02-03
- Granted: 2013-09-24
- Earliest claimed: 2007-12-24
- Assignees: Oxford Biotherapeutics Ltd
- Applicants: Christian Rohlff; Alasdair Stamps
- Inventors: Christian Rohlff; Alasdair Stamps
- Web page: https://patentgrep.com/patent/US8540998B2

## CPC

- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61P 35/00: Antineoplastic agents
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- G01N 33/74: involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors}
- C12Q 2600/136: Screening for pharmacological compounds
- G01N 2333/71: for growth factors; for growth regulators
- Y10T 436/143333: Saccharide [e.g., DNA, etc.]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, lung cancer or pancreatic cancer, for monitoring the effectiveness of bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, lung cancer or pancreatic cancer treatment, and for drug development based on Ephrin Type-A Receptor 10 Protein.

## Claims

### Claim 1

A method for treating a cancer wherein Ephrin type-A receptor 10 is overexpressed and the cancers are selected from bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, lung cancer or pancreatic cancer, the method comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising an antibody that specifically binds to Ephrin type-A receptor 10, wherein said antibody comprises a conjugated cytotoxic agent, and a pharmaceutically acceptable diluent or carrier wherein said treatment is cytotoxicity.

### Claim 2 (depends on 1)

A method according to claim 1 wherein said antibody is selected from the group consisting of an isolated monoclonal antibody, an antibody fragment, a humanized antibody and a chimeric antibody.